Cognition Therapeutics Files 8-K

TL;DR

Cognition Therapeutics filed an 8-K, expect updates soon.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on December 18, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Cognition Therapeutics has made a significant regulatory submission, which could signal important developments in their business operations or financial status.

Risk Assessment

Risk Level: medium — The filing is a standard 8-K, but the lack of specific details about the 'Other Events' makes it difficult to assess the immediate impact or risk.

Key Players & Entities

• Cognition Therapeutics, Inc. (company) — Registrant
• December 18, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-40886 (identifier) — SEC File Number
• 13-4365359 (identifier) — I.R.S. Employer Identification No.
• 2500 Westchester Avenue Purchase, NY 10577 (address) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar

Filing Documents

• tm2431405d1_8k.htm (8-K) — 25KB
• tm2431405d1_ex99-1.htm (EX-99.1) — 39KB
• tm2431405d1_ex99-1img001.jpg (GRAPHIC) — 344KB
• tm2431405d1_ex99-1img002.jpg (GRAPHIC) — 153KB
• tm2431405d1_ex99-1img003.jpg (GRAPHIC) — 248KB
• tm2431405d1_ex99-1img004.jpg (GRAPHIC) — 157KB
• tm2431405d1_ex99-1img005.jpg (GRAPHIC) — 152KB
• tm2431405d1_ex99-1img006.jpg (GRAPHIC) — 202KB
• tm2431405d1_ex99-1img007.jpg (GRAPHIC) — 132KB
• tm2431405d1_ex99-1img008.jpg (GRAPHIC) — 170KB
• tm2431405d1_ex99-1img009.jpg (GRAPHIC) — 179KB
• tm2431405d1_ex99-1img010.jpg (GRAPHIC) — 172KB
• tm2431405d1_ex99-1img011.jpg (GRAPHIC) — 137KB
• tm2431405d1_ex99-1img012.jpg (GRAPHIC) — 141KB
• tm2431405d1_ex99-1img013.jpg (GRAPHIC) — 174KB
• tm2431405d1_ex99-1img014.jpg (GRAPHIC) — 220KB
• tm2431405d1_ex99-1img015.jpg (GRAPHIC) — 161KB
• tm2431405d1_ex99-1img016.jpg (GRAPHIC) — 148KB
• tm2431405d1_ex99-1img017.jpg (GRAPHIC) — 152KB
• tm2431405d1_ex99-1img018.jpg (GRAPHIC) — 208KB
• tm2431405d1_ex99-1img019.jpg (GRAPHIC) — 206KB
• tm2431405d1_ex99-1img020.jpg (GRAPHIC) — 193KB
• tm2431405d1_ex99-1img021.jpg (GRAPHIC) — 191KB
• tm2431405d1_ex99-1img022.jpg (GRAPHIC) — 168KB
• tm2431405d1_ex99-1img023.jpg (GRAPHIC) — 131KB
• tm2431405d1_ex99-1img024.jpg (GRAPHIC) — 168KB
• 0001104659-24-129619.txt ( ) — 6181KB
• cgtx-20241218.xsd (EX-101.SCH) — 3KB
• cgtx-20241218_lab.xml (EX-101.LAB) — 33KB
• cgtx-20241218_pre.xml (EX-101.PRE) — 22KB
• tm2431405d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. Cognition Therapeutics, Inc. (the "Company") has made available a slide presentation relating to the topline data from its Phase 2 COG1201 SHIMMER study, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Corporate presentation of Cognition Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: December 18, 2024 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR